C1 gene expression platform: Rapid, high yield and lower cost way to develop and manufacture biologics

Authors

• Mark Emalfarb, CEO of Dyadic International, Inc.Follow
• Ronen Tchelet, Dyadic International Inc., 1044 North US Hwy 1 Suite 201, USA
• Noelia Valbuena, Dyadic International Inc., 1044 North US Hwy 1 Suite 201, USA
• Joseph Hazelton, Dyadic International Inc., 1044 North US Hwy 1 Suite 201, USA

Conference Dates

May 19 - 24, 2024

Abstract

Please click Additional Files below to see the full abstract

Recommended Citation

Mark Emalfarb, Ronen Tchelet, Noelia Valbuena, and Joseph Hazelton, "C1 gene expression platform: Rapid, high yield and lower cost way to develop and manufacture biologics" in "Vaccine Technology IX", Linda Lua, The University of Queensland, Australia; Charles Lutsch, Sanofi-Vaccines, France; Francesc Gòdia, Universitat Autònoma de Barcelona (UAB), Spain; Tara Tagmyer, CMC Leader, USA Eds, ECI Symposium Series, (2024). https://dc.engconfintl.org/vaccine_ix/106